Funded vaccines for special groups from 1st January 2017

Funded vaccines for special groups from 1st January 2017 Please refer to individual vaccines for detailed eligibility criteria and to the electronic Immunisation Handbook 2014 (3rd edition) for vaccine administration schedules Asplenia — Functional or Pre- or Post-Splenectomy Immunisation Programme • Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines Chemotherapy — following • Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines Also consider immunosuppression for longer than 28 days • Hepatitis B and meningococcal vaccines Cochlear implant • Hib, influenza, and pneumococcal vaccines Error of metabolism at risk of major metabolic decompensation • Influenza and varicella vaccines Haematopoietic stem cell transplantation (HSCT) — following • Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines Also consider immunosuppression for longer than 28 days • Hepatitis B vaccine Hepatitis A case — contact with • Hepatitis A vaccine Hepatitis B case — contact with Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive • Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth Household and sexual contacts of known acute hepatitis B cases or carriers • Hepatitis B vaccine Hepatitis C positive individual • Hepatitis B vaccine HIV positive individual • Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines Immune deficiency/immunosuppression Individuals with an immune deficiency • Influenza, meningococcal, and pneumococcal vaccines Household contacts of children or adults who will be/are immunosuppressed • Varicella vaccine Prior to elective immunosuppression for longer than 28 days • Varicella vaccine Following immunosuppression for longer than 28 days • Hepatitis B, Hib, influenza, meningococcal, and Tdap vaccines

Influenza Immunisation Programme »» Pregnancy, »» Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness, »» Individuals aged 6 months to under 65 years with an eligible medical condition, »» Individuals aged 65 years or older.

• Influenza vaccine Kidney disease • Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines Liver disease • Hepatitis A and varicella vaccines Meningococcal disease case — contact with • Meningococcal vaccine Needle stick injury — following • Hepatitis B vaccine Non-consensual sexual intercourse — following • Hepatitis B vaccine Pneumococcal disease — increased risk • Additional pneumococcal vaccines Pregnancy • Influenza and Tdap vaccines in every pregnancy Rubella — women of childbearing age who are not immune to rubella • MMR vaccine Solid organ transplantation Prior to solid organ transplantation • Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines Following solid organ transplantation • Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines Tuberculosis — infants and children aged under 5 years at risk of tuberculosis (TB) exposure • BCG vaccine

Vaccine key – BCG: tuberculosis; Hib: Haemophilus influenzae type b; HPV: human papillomavirus; MMR: measles, mumps, rubella; Tdap: tetanus, diphtheria, acellular pertussis; varicella: chickenpox.

Funded vaccines for special groups from 1st January 2017

#

Vaccine

Individuals eligible for funded vaccine

Hepatitis A vaccine (Chapter 7#)

• One dose for close contacts of a hepatitis A case • Two doses for transplant patients; or children with chronic liver disease

Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (Chapter 8#)

• Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*; non-consensual sexual intercourse; or needle stick injury (5mcg/0.5mL or 10mcg/1.0mL as appropriate) • Children under the age of 18 years who are considered not to have achieved a positive serology and require additional vaccination (5mcg/0.5mL or 10mcg/1.0mL as appropriate) • Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg/1.0mL)

Haemophilus influenzae type b (Hib) vaccine (Chapter 6#)

• An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen

Human papillomavirus (HPV) vaccine (Chapter 9#)

• Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive • A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy

Influenza vaccine (Chapter 10# and the Influenza Kit)

• • • •

Meningococcal conjugate vaccines (MenCCV under 2 years and MCV4-D 2 years or older) (Chapter 12#)

• One dose for a close contacts of meningococcal disease case • Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days* • Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive

Tetanus, diphtheria and pertussis (Tdap) vaccine (Chapter 14#)

• One dose for pregnant women, between gestational weeks 28 and 38 of every pregnancy • Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; postchemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen

Pregnant women in every pregnancy during vaccination season Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness Individuals aged 65 years and older Individuals aged 6 months to under 65 years with certain medical conditions, as per the Influenza Kit, including individuals pre- or postsplenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation

Refer to recommended chapter in the electronic Immunisation Handbook 2014 3rd Edition.

* For example chemotherapy regimens to treat cancer, conditioning regimes prior to haematopoietic stem cell transplantation, and treatment of immune mediated inflammatory disease.

Fact sheet January 2017

Funded vaccines for special groups from 1st January 2017 Vaccine

Individuals eligible for funded vaccine

Pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (23PPV) vaccines (Chapter 15#)

PCV13: • One dose for high-risk children aged 18 months to under 18 years who have previously received four doses of PCV10 • Up to an additional four doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; postchemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive 23PPV: • Up to two doses (as appropriate) for high-risk children aged 2 years to under 18 years, or • Up to three doses (as appropriate) for individuals aged 18 years or older who are: • Post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive

BCG vaccine (Bacillus Calmette-Guérin) (Chapter 20#)

• All public health community BCG Vaccination Clinics and in-hospital vaccinations are postponed until further notice, due to a global shortage of BCG vaccine.

• Eligibility when BCG Vaccination Clinics are operational: • Infants at increased risk of tuberculosis (TB) exposure • Children aged under 5 years at risk of TB exposure

Varicella vaccine (Chapter 21#)

Two doses for non-immune individuals: • Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist • Prior to elective immunosuppressive therapy that will be longer than 28 daysΨ • With chronic liver disease who may in future be candidates for transplantation • With deteriorating renal function before transplantation • Pre-solid organ transplantation • Post-haematopoietic stem cell transplantation, on the advice of their specialist • Post-chemotherapy, on the advice of their specialist Two doses for individuals with no clinical history of varicella infection or immunisation: • With an inborn error of metabolism at risk of major metabolic decompensation • Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection of immunisation • Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation

# Ψ

Refer to recommended chapter in the electronic Immunisation Handbook 2014 3rd Edition.

For example treatment of immune mediated inflammatory disease.

Fact sheet January 2017